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MSM: man who has sex with men
SCCIS: squamous cell carcinoma in situINTRODUCTION
Human papillomavirus (HPV) is the causative
agent of condyloma acuminata (CA). Although it is
often assumed that CA are caused by HPV subtypes
distinct from those that lead to squamous
cell carcinoma, this is not always the case, particu-
larly in immunocompromised patients. A greater
percentage of HIV-positive men are infected with
multiple HPV subtypes within their CA than their
HIV-negative counterparts, with lower CD4 counts
associated with higher levels of oncogenic HPV
DNA. In addition, HIV-positive individuals have a
higher prevalence and incidence of HPV-associated
anal intraepithelial neoplasia (AIN) and anogenital
cancers than their HIV-negative counterparts.
Furthermore, many instances of malignant
transformation of CA have been described. Here
we show the spectrum and progression of disease
from CA to aggressive anogenital squamous cell
carcinoma in 3 HIV-positive patients and stress the
diversity of clinical presentations that can exist in this
patient population. Immunosuppression from
HIV infection, co-infection with multiple HPV
subtypes including oncogenic strains, a history of a
low CD4 nadir, and the inability to adequately clear
the HPV puts patients at a much greater risk of
malignant progression of HPV-associated skin
lesions, which can be rapid in some cases. Hence,
it is critical that dermatologists screen patients and
those affected receive close clinical monitoring,
disease surveillance, and appropriate prompt
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enn.edu.CASE REPORTS
Patient 1
An HIV-positive man in his 20s with a history of
smoking, asthma, and pneumocystis pneumonia
presented with numerous raised 2-mm condylomata
on his penile shaft and anus. The patient was
recently incarcerated and had sexual activity with
more than 20 male and female partners. The patient
had been inconsistent with his antiretroviral (ARV)
regimen (efavirenz, emtricitabine, tenofovir, and
ritonavir-boosted atazanavir) since his HIV diagnosis
(baseline CD4 count of 22 cells per microliter). After
restarting ARV therapy, his CD4 count increased and
his viral load decreased; however, 8 months later the
condylomata remained stable and continued to be
unresponsive to imiquimod 5% 3 times weekly.
The patient did not return for 18 months. He
presented with more than 20 skin-colored and
hyperpigmented verrucous papules on his penile
shaft, grouped hyperpigmented papules extending
to the anal verge on his perianal skin, and a
pedunculated 1-cm verrucous nodule on his right
perianal skin. He underwent cryotherapy to theJAAD Case Reports 2016;2:47-50.
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Fig 1. Biopsy of pedunculated perianal lesion from
patient 1. The biopsy shows a pedunculated condyloma
with a transition zone to SCCIS (Hematoxylin-eosin stain;
original magnification: 340.)
Fig 2. HPV-16 immunostaining of the lesion in Fig 1.
Significant HPV-16 nuclear staining is observed within the
pedunculated lesion excised from patient 1. HPV-16
staining can be seen within the SCCIS region of the
specimen (arrow 1) and within the adjacent condyloma
(arrow 2) (original magnification: 340.)
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shave excision of the pedunculated lesion on his
perianal skin. The biopsy found a pedunculated
condyloma with a transition zone to squamous cell
carcinoma in situ (Fig 1) with HPV-16 positivity
(Fig 2). Imiquimod 5% was prescribed for treatment
5 times weekly for the remaining condyloma.
Although we emphasized to the patient the impor-
tance of complete treatment, he was once again lost
to follow-up.Patient 2
A man in his 40s with a long history of
HIV positivity, moderate-to-heavy smoking, dis-
seminated Kaposi’s sarcoma, HPV-related oral
leukoplakia (and subsequent invasive squamous
cell carcinoma; Fig 3), HPV-related rectal cancer in
remission, and a CD4 count less than 200 cells per
microliter presented for evaluation and treatment of
condylomata on the penis and perianal region. A
diagnosis of CA was rendered; however, 1 lesion on
the penis was larger and more atypical than the
others, and a biopsy was performed. Histologically,
the penile lesion showed squamous cell carcinoma
in situ (SCCIS). The patient was treated with a
combination of cryotherapy and imiquimod 5%.
Over the next few months, the patient continued
to have an excellent response to imiquimod 5%, with
complete resolution of his penile CA. However, the
patient then began experiencing perianal bleeding,
and on physical examination was found to have a
new perianal erosion suspicious for malignancy.
Histologically, biopsies found SCCIS in the perianal
area, and the patient was treated with imiquimod.
Over the next year, the patient’s CD4 count increased
to 217 cells per microliter, and his viral load became
undetectable, and all evidence of his perianal CA
resolved.The patient remained clear of his perianal CA for
3 years, at which point a concerning new perianal
thin red plaque was noted. A biopsy of the lesion
found recurrent SCCIS, and an excision was
performed. Results of a follow-up anoscopy were
normal, and the patient was counseled to undergo an
annual anoscopy because of his high risk of anal
dysplasia and recurrent anal cancer.Patient 3
An HIV-positive (baseline CD4 count of 138 cells
per microliter [20%], viral load of 33,453 copies per
milliliter) man in his 20s with a history of central
nervous system toxoplasmosis and perianal CA
presented in acute renal failure and with a recent
history of rectal bleeding. The patient identified as a
man who has sex with men (MSM). Upon admission,
random biopsies of his rectum during colonoscopy
found histologic changes consistent with HPV and
low-grade AIN-1. The patient’s CD4 count at this time
was 77 cells per microliter, and he was started on
ARV therapy (Truvada and ritonavir-boosted
darunavir).
Over the next 6 months, the patient tolerated his
ARV regimen well, with his CD4 count increasing to
120 cells per microliter and his viral load decreasing.
However, the patient’s lesions did not improve, and
he presented for evaluation of a new painful partially
prolapsed ulcerated lesion emanating from his anal
canal. The patient underwent successful transanal
excision of this anal canal mass and distal anal canal
condyloma fulguration and excision. He also had
new anal and perianal condyloma lesions. Excisional
biopsies of these lesions were found to be a mixture
Fig 3. HPV-related oral leukoplakia with biopsy-proven invasive squamous cell carcinoma.
This is the clinical appearance before Mohs surgery (A) and after clearance of the tumor (B).
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intraepithelial lesions. Imiquimod 5% was also
prescribed, as the patient’s lesions started to involve
the perianal skin as well. However, the aggressive
course that the patient’s disease ultimately followed
led him to require a systemic therapy for his disease.
The patient again presented to the emergency
room with rectal bleeding and on flexible sigmoid-
oscopy was found to have a rectal mass that was
partially obstructing and bleeding. On digital rectal
examination, a large friable bleeding sessile fixated
mass approximately 4 cm from the anal verge was
found tethered to the rectal wall, encompassing 75%
of the circumference of the lumen. Histologically,
biopsies results of the lesion were conclusive for
invasive squamous cell carcinoma.
The patient underwent computed tomography
scanning for staging, which showed multiple
pulmonary nodules and liver lesions in keeping
with stage IV squamous cell carcinoma. The patient
was referred for palliative systemic chemotherapy
with cisplatin and fluorouracil (dose adjusted) plus
definitive local radiation to the anorectal mass.
DISCUSSION
HPV is the causative agent of CA, and certain HPV
subtypes are also responsible for causing some forms
of genital cancers.1 Although CA are often
considered to be caused by HPV subtypes distinct
from those that lead to squamous cell carcinoma, we
now know this to be a dangerous assumption to
make clinically, particularly in certain populations
such as immunocompromised patients. Infections
with multiple HPV types in CA are common,2 and
many instances of co-infection with oncogenic HPV
and malignant transformation of condyloma
have been described. We now have a betterunderstanding that sexual transmission of oncogenic
HPV subtypes is likely responsible for many
squamous cell malignancies that occur in the
anogenital tract of both men and women.3
Previous studies have reported a higher preva-
lence and incidence of anogenital HPV infection in
HIV-positive MSM than in HIV-negative MSM.4,5
Consistent with this, HIV-positive men and women
have a higher prevalence and incidence of HPV-
associated AIN and anogenital cancers than their
healthy HIV-negative counterparts.6 The incidence
of anal cancer in HIV-positive MSM was found to be
twice as high than in their HIV-negative counterparts
in one study.7 The relative risk of anal cancer among
HIV-positive men and women was reported to be
37.9-fold and 6.8-fold higher, respectively, than that
in the general population; the relative risk of penile
cancer among HIV-positive men was 3.7-fold higher
than that in the general population.8
Furthermore, although the HPV subtypes detect-
able in the anal canal of HIV-positive and
HIV-negative men are similar, one study found that
73% of HIV-positive menwere infectedwith multiple
HPV types compared with only 23% of HIV-negative
men, with HPV-16 the most common subtype.9
Among these HIV-positive men, lower CD4 counts
were associated with higher levels of oncogenic HPV
subtypes DNA (HPV-16/18/31/33/35/39/45/51/52/
56/58), suggesting increased replication of these
subtypes with more advanced immunosuppression.9
Evidence suggests that this increased risk may be a
result of HIV-associated disruption of epithelial tight
junctions, which, in the context of attenuated
immunity, may potentiate HPV infection, reduce
viral clearance, and ultimately contribute to the
higher prevalence and incidence of HPV-associated
neoplasia in this population.10 Other risk factors for
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5-fold increased risk), a history of sexually
transmitted infections, and smoking.11
In our series, we found that it is often unclear
whether the development of squamous cell malig-
nancies fromCA are caused by true transformation or
the concomitant presence of multiple HPV subtypes
(including oncogenic subtypes) in adjacent skin, but
true transformation does occur in some instances.
Although the ARV regimens now available are un-
doubtedly more efficacious than ever before, with
HIV patients recovering CD4 counts and suppressing
viral loads, a clinician must take care not to assume
the CA of an HIV patient will behave in a benign
manner, as they likely would in their otherwise
healthy counterparts. Existing data suggest that
even if a patient has been on an ARV regimen for
an extended period, a history of HPV infection at the
time of a low CD4 nadir puts them at a much greater
risk of malignant progression of HPV-associated skin
lesions.
Because the rate of progression from CA to
squamous cell malignancy is unpredictable, a patient
may initially present with benign-appearing CA but
in reality be infectedwith an oncogenic HPV subtype
masquerading as benign CA. A patient’s CA may
remain stable for years without transformation, as in
the case of our first patient, but could also progress as
far as incurable metastatic squamous cell carcinoma
in a manner of months, as in the case of our third
patient. Others may have a continuous long-term
battle with HPV-related dysplasia, as in the case of
our second patient. Hence, it is critical that all HIV
patients, especially those with a history of HPV, be
examined in the genital and anal areas on a regular
basis to evaluate for new or recurrent disease and the
need for treatment. There should be a low threshold
for biopsies to rule out malignant progression andregular clinical surveillance through physical exam-
ination and malignancy screening.
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